N-ras oncogene-induced gene expression in human hematopoietic progenitor cells: Upregulation of p16INK4a and p21CIP1/WAF1 correlates with myeloid differentiation

Experimental Hematology

Volumn 35, Issue 6, 2007, Pages 908-919

  Shen, Sylvie ^a   Passioura, Toby ^b   Symonds, Geoff ^a,b   Dolnikov, Alla ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 1; METHYLCELLULOSE; PROTEIN P16INK4A;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SELECTION; CELL SUBPOPULATION; CELL SUSPENSION; CONTROLLED STUDY; DNA MICROARRAY; ERYTHROID CELL; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; ONCOGENE N RAS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENE; UNINDEXED SEQUENCE; UPREGULATION;

ANIMALS; ANTIGENS, CD34; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOKINES; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, RAS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; MUTATION, MISSENSE; MYELODYSPLASTIC SYNDROMES; MYELOID PROGENITOR CELLS; UP-REGULATION;

EID: 34249059656     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.02.011     Document Type: Article

References (34)

1. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 (1997) 730-737
2. Passegue E., Jamieson C.H., Ailles L.E., and Weissman I.L. Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. Proc Natl Acad Sci U S A 100 (2003) 11842-11849
3. Radich J.P., Kopecky K.J., Willman C.L., et al. N-ras mutations in adult de novo acute myelogenous leukemia: Prevalence and clinical significance. Blood 76 (1990) 801-807
4. Neubauer A., Dodge R.K., George S.L., et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 83 (1994) 1603-1611
5. Neubauer A., Greenberg P., Negrin R., Ginzton N., and Liu E. Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. Leukemia 8 (1994) 638-641
6. Feramisco J.R., Clark R., Wong G., Arnheim N., Milley R., and McCormick F. Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein. Nature 314 (1985) 639-642
7. Grugel S., Finkenzeller G., Weindel K., Barleon B., and Marme D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 270 (1995) 25915-25919
8. Serrano M., Lin A.W., McCurrach M.E., Beach D., and Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88 (1997) 593-602
9. Bond J., Jones C., Haughton M., DeMicco C., Kipling D., and Wynford-Thomas D. Direct evidence from siRNA-directed "knock down" that p16(INK4a) is required for human fibroblast senescence and for limiting ras-induced epithelial cell proliferation. Exp Cell Res 292 (2004) 151-156
10. Takaoka M., Harada H., Deramaudt T.B., et al. Ha-Ras(G12 V) induces senescence in primary and immortalized human esophageal keratinocytes with p53 dysfunction. Oncogene 23 (2004) 6760-6768
11. Ferbeyre G., de Stanchina E., Querido E., Baptiste N., Prives C., and Lowe S.W. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14 (2000) 2015-2027
12. Peeper D.S., Dannenberg J.H., Douma S., te Riele H., and Bernards R. Escape from premature senescence is not sufficient for oncogenic transformation by Ras. Nat Cell Biol 3 (2001) 198-203
13. Maher J., Baker D.A., Manning M., Dibb N.J., and Roberts I.A. Evidence for cell-specific differences in transformation by N-, H- and K-ras. Oncogene 11 (1995) 1639-1647
14. Maher J., Baker D., Dibb N., and Roberts I. Mutant ras promotes haemopoietic cell proliferation or differentiation in a cell-specific manner. Leukemia 10 (1996) 83-90
15. Gallagher A.P., Burnett A.K., Bowen D.T., and Darley R.L. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process. Cancer Res 58 (1998) 2029-2035
16. Darley R.L., and Burnett A.K. Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors. Exp Hematol 27 (1999) 1599-1608
17. Delgado M.D., Vaque J.P., Arozarena I., et al. H-, K- and N-ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism. Oncogene 19 (2000) 783-790
18. Matsumura I., Kawasaki A., Tanaka H., et al. Biologic significance of GATA-1 activities in Ras-mediated megakaryocytic differentiation of hematopoietic cell lines. Blood 96 (2000) 2440-2450
19. Dolnikov A., Shen S., Millington M., et al. A sensitive dual-fluorescence reporter system enables positive selection of ras suppressors by suppression of ras-induced apoptosis. Cancer Gene Ther 10 (2003) 745-754
20. Passioura T., Dolnikov A., Shen S., and Symonds G. N-ras-induced growth suppression of myeloid cells is mediated by IRF-1. Cancer Res 65 (2005) 797-804
21. MacKenzie K.L., Dolnikov A., Millington M., Shounan Y., and Symonds G. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood 93 (1999) 2043-2056
22. Chan I.T., Kutok J.L., Williams I.R., et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 113 (2004) 528-538
23. + cells. J Exp Med 185 (1997) 1337-1347
24. Darley R.L., Pearn L., Omidvar N., et al. Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells. Blood 100 (2002) 4185-4192
25. + hematopoietic progenitor cells into myeloid differentiation and proliferation both in vitro and in the NOD/SCID mouse. Exp Hematol 32 (2004) 852-860
26. Braig M., Lee S., Loddenkemper C., et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436 7051 (2005 Aug 4) 660-665
27. Lloyd A.C., Obermuller F., Staddon S., Barth C.F., McMahon M., and Land H. Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev 11 5 (1997 Mar 1) 663-677
28. Woods D., Parry D., Cherwinski H., Bosch E., Lees E., and McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17 9 (1997 Sep) 5598-5611
29. Lin A.W., Barradas M., Stone J.C., van Aelst L., Serrano M., and Lowe S.W. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 12 19 (1998 Oct 1) 3008-3019
30. Zhu J., Woods D., McMahon M., and Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 12 19 (1998 Oct 1) 2997-3007
31. Pumiglia K.M., and Decker S.J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci U S A 94 2 (1997 Jan 21) 448-452
32. Dorrell C., Takenaka K., Minden M.D., Hawley R.G., and Dick J.E. Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition. Mol Cell Biol 24 (2004) 6993-7002
33. Braun B.S., Tuveson D.A., Kong N., et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A 101 (2004) 597-602
34. G12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5 (2004) 375-387